GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CeriBell Inc (NAS:CBLL) » Definitions » Total Current Liabilities

CBLL (CeriBell) Total Current Liabilities : $11.83 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is CeriBell Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. CeriBell's total current liabilities for the quarter that ended in Mar. 2025 was $11.83

CeriBell Total Current Liabilities Historical Data

The historical data trend for CeriBell's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CeriBell Total Current Liabilities Chart

CeriBell Annual Data
Trend Dec22 Dec23 Dec24
Total Current Liabilities
9.86 21.60 12.99

CeriBell Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Current Liabilities Get a 7-Day Free Trial - 10.46 13.09 12.99 11.83

CeriBell Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

CeriBell's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=6.804+1.088
+Other Current Liabilities+Current Deferred Liabilities
=5+0.097
=12.99

CeriBell's Total Current Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.349+1.117
+Other Current Liabilities+Current Deferred Liabilities
=3.163+0.202
=11.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

CeriBell Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of CeriBell's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CeriBell Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CeriBell Inc (NAS:CBLL) » Definitions » Total Current Liabilities
Comparable Companies
OFIX TANAF KIDS AVNS BVS BFLY SENS RXST SIBN CTKB ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE
Traded in Other Exchanges
N/A
Address
360 N. Pastoria Avenue, Sunnyvale, CA, USA, 94085
Website
https://www.ceribell.com
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.